For a patient with adult ADHD whose Adderall IR prescription has gone unfilled for three weeks, the standard advice from a clinician is some version of: start calling pharmacies. That patient population, along with people on Ozempic, methylphenidate, clonazepam, and a long list of specialty and limited-distribution drugs, is the lede here. Medfinder, a Boston-based healthtech company founded by Parth Shah and a co-founder credited publicly as Dagget, sells those patients a concrete service: it locates a pharmacy near them that actually has the medication in stock, and it does so for a one-time fee rather than a subscription [Medfinder].
The company frames the problem in human terms. Its own about page claims the average American spends almost 100 hours a year navigating healthcare, a figure that is self-reported and not independently verified [Medfinder]. The relevant clinical context is more concrete. The U.S. has been working through multi-year shortages of stimulant medications used to treat ADHD and GLP-1 agonists used in type 2 diabetes and obesity, both tracked on the FDA Drug Shortages list. Standard of care today, when a prescription cannot be filled, looks roughly like this: the prescriber writes the script, the patient discovers the shortage at the counter, and the patient (or sometimes a clinic staffer) phones pharmacies one by one until something turns up, or switches to an alternative agent if the clinical picture allows. There is no national, real-time inventory feed for controlled substances, and DEA scheduling rules limit how freely a prescription for a Schedule II drug like Adderall can be transferred between pharmacies. Medfinder is selling a workaround for exactly that gap.
The bet
The product is deliberately narrow. A patient picks a search package, names the drug and dose, and Medfinder returns pharmacies in the area that have it on the shelf. Pricing is presented as one-time fees with no subscriptions, available as single or multi-search packages [Medfinder]. The mechanics behind the search are unusually low-tech for a company that lists itself as software: Quartz reported that Medfinder outsources the detective work of calling pharmacies to freelancers abroad [Quartz]. That is a design choice with real tradeoffs. It avoids the years-long integration slog of trying to plug into pharmacy management systems, and it sidesteps the question of whether chains would even share inventory data. It also means unit economics are tied to human labor rather than software margins, at least for now.
The second product line is aimed at prescribers. Medfinder for Providers is pitched as a way for clinics to help patients shop for a pharmacy without changing the prescriber's workflow [Medfinder]. That is the more interesting commercial wedge. A neurology or psychiatry practice that loses hours per week to pharmacy triage has a clear willingness to pay, and the B2B2C label the company uses suggests the long-term model routes through providers rather than direct-to-patient acquisition alone.
Why it could matter
Drug shortages in the United States are not a transient story. The FDA's shortage list has hovered near multi-decade highs, and stimulant shortages in particular have persisted since 2022. The patient population affected is large, motivated, and already paying out of pocket for workarounds (telehealth visits, GoodRx coupons, mail-order pharmacies). A service that reliably shortens the search from days to hours is the kind of thing patients tell each other about, which is consistent with the customer reviews Medfinder has accumulated on Trustpilot describing successful finds for hard-to-fill prescriptions [Trustpilot].
There is also a regulatory tailwind worth naming carefully. The FDA and Congress have both signaled interest in better shortage transparency, and several state boards of pharmacy have explored inventory reporting requirements. None of that is law yet, and Medfinder is not waiting for it. The company is betting that the manual, human-in-the-loop approach is good enough today to build a customer base, and that better data plumbing can be layered in later.
Team and traction
Parth Shah is listed publicly as co-founder and CTO, based in Gainesville, Florida, with prior roles at Abilitare and the University of Florida between 2019 and 2021 [RocketReach]. Pain News Network, covering the launch in 2024, credited Shah and Dagget as the founding team [Pain News Network, 2024]. Wellfound lists the company as having between one and ten employees, headquartered in Boston, with an in-office engineering role posted at $125,000 to $155,000 plus equity [Wellfound]. The brand itself was previously known as Insito Medfinder before a rename the company described on its own blog [Medfinder].
| Data point | Value | Source |
|---|---|---|
| Headquarters | Boston | Wellfound |
| Headcount band | 1-10 | Wellfound |
| Engineering salary band | $125k-$155k | Wellfound |
| Pricing model | One-time search fees | Medfinder |
| Public launch coverage | August 2024 | Pain News Network |
The honest counterfactual
The sharpest bear case is competitive. GoodRx already sits between patients and pharmacies at enormous scale, and its pricing pages indirectly signal stock at a given location, a workaround Medfinder's own blog acknowledges [Medfinder]. If GoodRx, Amazon Pharmacy, or a PBM-owned property decided to ship a real-time stock locator, a small Boston startup with a manual ops backend would face serious pressure. The bull answer is that none of those incumbents has shipped that product despite years of opportunity, likely because pharmacy chains have little incentive to expose live inventory to a price-comparison aggregator. Medfinder's manual approach, awkward as it sounds, may be precisely what lets it operate in the gap the incumbents cannot easily close. A second concern is data handling: routing patient-identified medication queries through overseas freelancers raises HIPAA-adjacent questions that the company will need to answer crisply as it sells into provider organizations. Medfinder publishes a privacy policy [Medfinder], and the provider-facing product will likely force a more formal compliance posture.
What to watch
The next twelve months should clarify two things. First, whether the provider product gains paid pilots with clinics in high-shortage specialties (psychiatry, endocrinology, pain management), which would validate the B2B2C thesis and pull the company off pure consumer transactions. Second, whether Medfinder discloses a priced funding round; the company is described as seed stage with investors not yet public, and a named lead would tell the market who is underwriting the bet. For now, the patient at the pharmacy counter is still the protagonist, and Medfinder is one of the few companies treating that moment as a product problem worth solving.
Pulse Raman, Health and Bio Correspondent, Startuply.